Luteal phase consequences of low-dose gonadotropin-releasing hormone agonist therapy in nonluteal-supported in vitro fertilization cycles**Supported in part by the Vicksburg Hospital Medical Foundation, Vicksburg, Mississippi.
1995 ◽
Vol 64
(3)
◽
pp. 573-576
◽
2001 ◽
Vol 76
(3)
◽
pp. 532-537
◽
2005 ◽
Vol 84
(6)
◽
pp. 1783-1785
◽
2002 ◽
Vol 78
(4)
◽
pp. 699-704
◽
2000 ◽
Vol 70
◽
pp. D40-D40
2015 ◽
Vol 16
(2)
◽
pp. 96-101
◽